1. Academic Validation
  2. Machine Learning Models Identify New Inhibitors for Human OATP1B1

Machine Learning Models Identify New Inhibitors for Human OATP1B1

  • Mol Pharm. 2022 Oct 21. doi: 10.1021/acs.molpharmaceut.2c00662.
Thomas R Lane 1 Fabio Urbina 1 Xiaohong Zhang 2 Margret Fye 2 Jacob Gerlach 1 Stephen H Wright 2 Sean Ekins 1
Affiliations

Affiliations

  • 1 Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510 Raleigh, North Carolina 27606, United States.
  • 2 Department of Physiology, College of Medicine, University of Arizona, Tucson, Arizona 85724, United States.
Abstract

The uptake transporter OATP1B1 (SLC01B1) is largely localized to the sinusoidal membrane of hepatocytes and is a known victim of unwanted drug-drug interactions. Computational models are useful for identifying potential substrates and/or inhibitors of clinically relevant transporters. Our goal was to generate OATP1B1 in vitro inhibition data for [3H] estrone-3-sulfate (E3S) transport in CHO cells and use it to build machine learning models to facilitate a comparison of seven different classification models (Deep learning, Adaboosted decision trees, Bernoulli naïve bayes, k-nearest neighbors (knn), random forest, support vector classifier (SVC), logistic regression (lreg), and XGBoost (xgb)] using ECFP6 fingerprints to perform 5-fold, nested cross validation. In addition, we compared models using 3D pharmacophores, simple chemical descriptors alone or plus ECFP6, as well as ECFP4 and ECFP8 fingerprints. Several machine learning algorithms (SVC, lreg, xgb, and knn) had excellent nested cross validation statistics, particularly for accuracy, AUC, and specificity. An external test set containing 207 unique compounds not in the training set demonstrated that at every threshold SVC outperformed the other algorithms based on a rank normalized score. A prospective validation test set was chosen using prediction scores from the SVC models with ECFP fingerprints and were tested in vitro with 15 of 19 compounds (84% accuracy) predicted as active (≥20% inhibition) showed inhibition. Of these compounds, six (abamectin, asiaticoside, berbamine, doramectin, mobocertinib, and umbralisib) appear to be novel inhibitors of OATP1B1 not previously reported. These validated machine learning models can now be used to make predictions for drug-drug interactions for human OATP1B1 alongside other machine learning models for important drug transporters in our MegaTrans software.

Keywords

MegaTrans; OATP1B1; deep learning; drug discovery; machine learning; support vector machine; transporters.

Figures
Products
Inhibitors & Agonists
Other Products